Evidence mapPaperPMID 41597186Full record

ReviewCells2026

Non-Apoptotic Programmed Cell Death: From Ultrastructural Characterization to Emerging Therapeutic Opportunities.

Philip Steiner, Lena Wiesbauer, Hubert H Kerschbaum, Susanna Zierler

Abstract readReview
In one paragraph

Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Philip SteinerInstitute of Pharmacology, Faculty of Medicine, Johannes Kepler University Linz, 4020 Linz, Austria.ORCID 0000-0003-3586-4231
Lena WiesbauerInstitute of Pharmacology, Faculty of Medicine, Johannes Kepler University Linz, 4020 Linz, Austria.
Hubert H KerschbaumDepartment of Biosciences and Medical Biology, Paris Lodron University Salzburg, 5020 Salzburg, Austria.ORCID 0000-0002-2923-886X
Susanna ZierlerInstitute of Pharmacology, Faculty of Medicine, Johannes Kepler University Linz, 4020 Linz, Austria.ORCID 0000-0002-4684-0385

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Distinct forms of non-apoptotic programmed cell death (PCD) play a central role in human and animal health and their signaling cascades provide pharmacological targets for therapeutic interventions. Non-apoptotic modalities of programmed cell death include well characterized forms, such as ferroptosis, necroptosis, pyroptosis, autophagy, paraptosis, as well as newly characterized varieties, such as cuproptosis, disulfidptosis, and erebosis. Each pathway exhibits unique molecular signaling signatures, ultrastructural characteristics, and functional outcomes that distinguish them from classical apoptosis. While pharmacological targets in the signaling cascade are promising objectives for overcoming apoptosis resistance in cancer therapy, inhibition of cell death in the myocardium or nervous system is critical for cytoprotection. This review provides detailed characterization and schematic visualization of cellular and subcellular hallmarks for each non-apoptotic PCD modality, facilitating their morphological identification. Understanding these diverse pathways is crucial for developing innovative therapeutic interventions in cancer, neurodegeneration, and inflammatory diseases.

Indexed as

AnimalsApoptosisAutophagyCuproptosisDisulfidptosisFerroptosisHumansNecroptosisNeoplasmsNeurodegenerative DiseasesParaptosisPyroptosisRegulated Cell DeathSignal Transductionautophagyautosiscancercaspase-independent cell deathferroptosisneurodegenerative diseasesnon-apoptotic cell deathprogrammed cell deathregulated cell deathultrastructure

Identifiers

PMID41597186
PMCPMC12839049

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.